Heart Failure Drugs Market Revenue 2024 to 2034
Heart Failure Drugs Market Revenue 2024 to 2034
The Heart Failure Drugs Market is projected to expand from USD 15.46 Bn in 2024 to USD 65.26 Bn by 2034, at a CAGR of 15.4%. Growth is driven by rising cardiovascular disease prevalence, advances in novel drug classes, and increasing adoption of combination therapies and personalized treatment approaches.
Report ID: 10365
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD 15.46 Bn
Forecast Year,
USD 65.26 Bn
CAGR, 2025 -
15.49%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Heart Failure Drugs Market Size Analysis
Heart Failure Drugs Market Size By Solution 2024 to 2034 (USD )
| Solution | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EHR/EMR | 3.40 | 3.94 | 4.56 | 5.26 | 6.07 | 7.01 | 8.05 | 9.29 | 10.79 | 12.49 | 14.43 |
| Analytics/AI | 3.09 | 3.56 | 4.12 | 4.74 | 5.50 | 6.33 | 7.31 | 8.47 | 9.82 | 11.31 | 13.06 |
| RCM/Billing | 2.78 | 3.21 | 3.71 | 4.30 | 4.96 | 5.72 | 6.57 | 7.58 | 8.71 | 10.06 | 11.68 |
| Telehealth | 2.47 | 2.86 | 3.31 | 3.82 | 4.40 | 5.09 | 5.92 | 6.84 | 7.87 | 9.09 | 10.47 |
| Cybersecurity | 1.55 | 1.78 | 2.05 | 2.38 | 2.74 | 3.16 | 3.68 | 4.25 | 4.89 | 5.64 | 6.54 |
| Others | 2.16 | 2.49 | 2.88 | 3.33 | 3.84 | 4.45 | 5.15 | 5.93 | 6.84 | 7.91 | 9.09 |
Heart Failure Drugs Market Size By Component 2024 to 2034 (USD )
| Component | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Services | 8.66 | 10.02 | 11.58 | 13.39 | 15.45 | 17.86 | 20.60 | 23.73 | 27.41 | 31.69 | 36.45 |
| Software | 5.26 | 6.05 | 6.97 | 8.05 | 9.31 | 10.74 | 12.45 | 14.47 | 16.75 | 19.32 | 22.36 |
| Hardware | 1.55 | 1.79 | 2.07 | 2.38 | 2.74 | 3.16 | 3.63 | 4.17 | 4.78 | 5.50 | 6.45 |
Heart Failure Drugs Market Size By End-User 2024 to 2034 (USD )
| End-User | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Providers | 8.35 | 9.62 | 11.15 | 12.90 | 14.87 | 17.18 | 19.87 | 22.98 | 26.54 | 30.66 | 35.38 |
| Payers | 4.02 | 4.66 | 5.35 | 6.14 | 7.10 | 8.20 | 9.46 | 10.98 | 12.70 | 14.65 | 16.95 |
| Life Sciences | 2.47 | 2.87 | 3.30 | 3.84 | 4.45 | 5.13 | 5.91 | 6.75 | 7.76 | 8.98 | 10.38 |
| Others | 0.62 | 0.71 | 0.82 | 0.94 | 1.09 | 1.25 | 1.44 | 1.66 | 1.93 | 2.22 | 2.56 |
Heart Failure Drugs Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 6.96 | 8.05 | 9.36 | 10.82 | 12.52 | 14.47 | 16.72 | 19.28 | 22.38 | 25.94 | 29.94 |
| Europe | 4.33 | 4.99 | 5.73 | 6.64 | 7.59 | 8.78 | 10.11 | 11.68 | 13.40 | 15.47 | 17.87 |
| Asia Pacific | 3.40 | 3.92 | 4.51 | 5.17 | 6.02 | 6.95 | 8.04 | 9.31 | 10.72 | 12.31 | 14.20 |
| Latin America | 0.46 | 0.54 | 0.62 | 0.72 | 0.82 | 0.95 | 1.10 | 1.26 | 1.46 | 1.68 | 1.96 |
| Middle East & Africa | 0.31 | 0.36 | 0.41 | 0.47 | 0.55 | 0.62 | 0.72 | 0.84 | 0.97 | 1.11 | 1.29 |
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
